MedTrace Logo

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-03-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.

Conditions

Interventions

BIOLOGICAL

BI-505

Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months

OTHER

High dose melphalan

High dose melphalan (HDM)

OTHER

Autologous stem cell transplantation

Autologous stem cell transplantation (ASCT)

Sponsors & Collaborators

  • BioInvent International AB

    lead INDUSTRY

Principal Investigators

  • Alfred Garfall, MD · Div of Hema/Onc, Dept.of Med, Perelman Center Advanced Med, Philadelphia PA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756728 on ClinicalTrials.gov